Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience

CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Palleschi, Michela, Maltoni, Roberta, Ravaioli, Sara, Vagheggini, Alessandro, Mannozzi, Francesca, Fanini, Francesca, Pirini, Francesca, Tumedei, Maria Maddalena, Barzotti, Eleonora, Cecconetto, Lorenzo, Sarti, Samanta, Manunta, Silvia, Possanzini, Paola, Fedeli, Anna, Curcio, Annalisa, Altini, Mattia, De Giorgi, Ugo, Rocca, Andrea, Bravaccini, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460222/
https://www.ncbi.nlm.nih.gov/pubmed/32784518
http://dx.doi.org/10.3390/diagnostics10080573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460222/
https://www.ncbi.nlm.nih.gov/pubmed/32784518
http://dx.doi.org/10.3390/diagnostics10080573

Ejemplares similares